Serum lipidomic profiling as a useful tool for screening potential biomarkers of hepatitis B-related hepatocellular carcinoma by ultraperformance liquid chromatography-mass spectrometry
Carregando...
Citações na Scopus
19
Tipo de produção
article
Data de publicação
2015
Título da Revista
ISSN da Revista
Título do Volume
Editora
BIOMED CENTRAL LTD
Autores
PASSOS-CASTILHO, Ana Maria
CARVALHO, Valdemir Melechco
CARDOZO, Karina Helena Morais
Citação
BMC CANCER, v.15, article ID 985, 9p, 2015
Resumo
Background: Chronic hepatitis B (CHB) virus infection is a major cause of hepatocellular carcinoma (HCC), as late diagnosis is the main factor for the poor survival of patients. There is an urgent need for accurate biomarkers for early diagnosis of HCC. The aim of the study was to explore the serum lipidome profiles of hepatitis B-related HCC to identify potential diagnostic biomarkers. Methods: An ultraperformance liquid chromatography mass spectrometry (UPLC-MS) lipidomic method was used to characterize serum profiles from HCC (n = 32), liver cirrhosis (LC) (n = 30), CHB (n = 25), and healthy subjects (n = 34). Patients were diagnosed by clinical laboratory and imaging evidence and all presented with CHB while healthy controls had normal liver function and no infectious diseases. Results: The UPLC-MS-based serum lipidomic profile provided more accurate diagnosis for LC patients than conventional alpha-fetoprotein (AFP) detection. HCC patients were discriminated from LC with 78 % sensitivity and 64 % specificity. In comparison, AFP showed sensitivity and specificity of 38 % and 93 %, respectively. HCC was differentiated from CHB with 100 % sensitivity and specificity using the UPLC-MS approach. Identified lipids comprised glycerophosphocolines, glycerophosphoserines and glycerophosphoinositols. Conclusions: UPLC-MS lipid profiling proved to be an efficient and convenient tool for diagnosis and screening of HCC in a high-risk population.
Palavras-chave
Biomarker, Hepatocellular carcinoma, Hepatitis B, Lipidomics, UPLC-MS, Diagnosis
Referências
- Bolondi L, 2003, J HEPATOL, V39, P1076, DOI 10.1016/S0168-8278(03)00349-0
- Patterson AD, 2011, CANCER RES, V71, P6590, DOI 10.1158/0008-5472.CAN-11-0885
- Sullentrop F, 2002, NMR BIOMED, V15, P60, DOI 10.1002/nbm.758
- Kikuchi L, 2013, ANTIVIR THER, V18, P445, DOI 10.3851/IMP2602
- Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516
- Kim CK, 2001, J ULTRAS MED, V20, P99
- Singal A, 2009, ALIMENT PHARM THER, V30, P37, DOI 10.1111/j.1365-2036.2009.04014.x
- BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911
- Carrilho FJ, 2010, CLINICS, V65, P1285, DOI 10.1590/S1807-59322010001200010
- Wang BH, 2012, J PROTEOME RES, V11, P1217, DOI 10.1021/pr2009252
- Zhou LN, 2012, ANAL BIOANAL CHEM, V403, P203, DOI 10.1007/s00216-012-5782-4
- Ott JJ, 2012, VACCINE, V30, P2212, DOI 10.1016/j.vaccine.2011.12.116
- Hu CX, 2009, J CHROMATOGR B, V877, P2836, DOI 10.1016/j.jchromb.2009.01.038
- Wenk MR, 2005, NAT REV DRUG DISCOV, V4, P594, DOI 10.1038/nrd1776
- McGlynn KA, 2015, CLIN LIVER DIS, V19, P223, DOI 10.1016/j.cld.2015.01.001
- Bruix J, 2011, HEPATOLOGY, V53, P1020, DOI 10.1002/hep.24199
- Diamond DL, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000719
- El-Serag HB, 2011, NEW ENGL J MED, V365, P1118, DOI 10.1056/NEJMra1001683
- Llovet JM, 2012, J HEPATOL, V56, P908
- Kimhofer T, 2015, BRIT J CANCER, V112, P1141, DOI 10.1038/bjc.2015.38
- Lewen Jia JC, 2008, METABOLOMICS, V4, P183
- Oehler N, 2014, HEPATOLOGY, V60, P1483, DOI 10.1002/hep.27159